ZYDUS PHARMACEUTICALS LTD
Quant Mutual Fund added 27 stocks to its portfolio in May. Do you own any?
Quant Mutual Fund is under Sebi inquiry for suspected front-running, leading to search and seizure operations in Mumbai and Hyderabad.
Zydus to make Biotax 1g injection available with 10ml sterile water post Nepal regulator's objection
The Indian pharmaceuticals group refuted a media report that the Department of Drug Administration, Nepal has suspended sales and distribution of Biotax 1gm due to "serious health risks" stating these were "misleading and erroneous" as it complies with all quality parameters as per approved specification.
Accumulate Zydus Lifesciences, target price Rs 1196: Geojit Financial Services
Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 105126.30 Crore) operating in Pharmaceuticals sector.
ChrysCapital sets sights on pharma buyout deals
ChrysCapital, led by MD Kshitij Sheth, aims to acquire Indian companies in the formulation business with potential valuations of $200 million-$500 million, focusing on growth and eventual public listings.
Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
Bayer acquires remaining 25% stake in Bayer Zydus Pharma Pvt Ltd to secure full ownership
Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited have concluded their joint venture, Bayer Zydus Pharma Private Limited (BZPPL), established in 2011 for pharmaceutical sales and marketing in India. Bayer is now acquiring full ownership of the entity as per pre-agreed terms. The joint venture successfully combined Zydus's Indian marketing expertise and distribution network with Bayer's global innovation, making strides in various therapeutic areas.
- Go To Page 1
Indian pharmaceutical industry set for major transformation: Dilip Shanghvi
At an annual meeting of the USA-India Chamber of Commerce in Boston, Shanghvi told a gathering of leading multinational drug makers about the "clear positive improvements" that are taking place in India. Sun Pharma itself has built a pipeline of over 10 specialty and innovative drugs in the US. It's done this through acquisitions of late-stage drugs in clinical trials and building commercial teams around them. For Indian companies that have grown by making copies of innovative drugs, gaining presence in innovative drugs is considered tough as this segment is dominated by giant corporations such as Pfizer, Novartis, Roche, Eli Lilly and Bristol Myers Squibb.
Eli Lilly could launch obesity drug in India next year, CEO says
Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lilly's drugs as well as Danish rival Novo Nordisk's in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diabetes.
Sun Pharma scouting for innovative therapies to boost India business
Approved by the Indian drug regulator in May 2023, sovateltide can be administered within 24 hours for the treatment of ischemic stroke, almost five times more than the narrow time window of 4-5 hours offered by current treatment options like tissue plasminogen activator (TPA) called thrombolytic drugs that dissolve the clots that cause strokes. An ischemic stroke is a medical emergency that occurs when blood supply to part of a brain is blocked or reduced.
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Torrent, Zydus in co-marketing pact for liver disease drug Saroglitazar
Torrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Under the agreement, Torrent gains semi-exclusive rights to market as VORXAR while Zydus continues marketing as Lipaglyn and Bilypsa. Licensing fees and milestone payments are part of the pact.
Why India needs to up the dose on R&D spend in pharmaceutical, medtech industry
The Indian pharma and medtech industry is on the cusp of big growth, and aims to grow to $500 billion by 2047. Thrust on R&D and innovation will be fundamental for this. GoI's Scheme for Promotion of Research and Innovation in Pharma-MedTech (PRIP) is a step in the right direction. Industry efforts must align with patient needs while emphasising accessibility, affordability and quality.
KRBL, Union Bank among 11 stocks with RSI trending down
In this article we delve into the significance of RSI, while exploring the intriguing case of 11 stocks whose RSI trended downward. We analyze these stocks, providing a comprehensive guide for investors seeking informed decision-making.
Adani Ports, Zomato among 10 stocks with bearish RSI
The intricacies of stock trading require astute decision-making. One critical tool in this endeavor is the Relative Strength Index (RSI), which helps assess stock trends. This article delves into RSI's importance, its role in evaluating stocks, and investigates 10 stocks in the overbought zone with bearish RSI trends.
Zomato, Sobha among 10 stocks with bearish RSI
The Relative Strength Index (RSI) is a crucial tool in evaluating stock movements and identifying potential reversals in momentum. Stocks with declining RSI trends while being in the overbought zone indicate the possibility of a bearish trend. ETMarkets has selected ten such overbought but bearish stocks based on a StockEdge report.
Sun Pharma, Lupin among 9 BSE Healthcare stocks that hit new 52-week highs on Thursday
The healthcare sector's impressive performance in the stock market highlights these companies' commitment to innovation, research, and delivering quality healthcare solutions to patients worldwide.
Stock market update: Nifty Pharma index advances 0.54%
The Nifty Pharma index closed 0.54 per cent up at 14092.6.
Stock market update: Nifty Pharma index advances 0.04% in an upbeat market
The Nifty Pharma index was trading 0.04 per cent up at 13942.4.
Stock market update: Nifty Pharma index advances 0.3%
The Nifty Pharma index closed 0.3 per cent up at 13936.7.
Stock market update: Nifty Pharma index advances 0.33% in an upbeat market
The Nifty Pharma index was trading 0.33 per cent up at 13940.95.
Stock market update: Nifty Pharma index advances 0.85% in an upbeat market
The Nifty Pharma index was trading 0.85 per cent up at 13869.05.
Stock market update: Nifty Pharma index advances 0.71%
The Nifty Pharma index closed 0.71 per cent up at 13772.0.
Stock market update: Nifty Pharma index advances 0.22% in a weak market
The Nifty Pharma index was trading 0.22 per cent up at 13705.05.
Stock market update: Nifty Pharma index advances 0.54% in an upbeat market
The Nifty Pharma index was trading 0.54 per cent up at 13696.45.
Load More
